Literature DB >> 7387000

The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study.

E B Leahey, J A Reiffel, E G Giardina, J T Bigger.   

Abstract

We compared the effects of quinidine and three alternate antiarrhythmic drugs on serum digoxin concentration in 63 patients before and during administration of quinidine, procainamide, disopyramide, or mexiletine. Quinidine increased digoxin concentration by at least 0.5 nmol/L in 21 of 22 patients: Mean serum digoxin rose from 1.2 nmol/L to 2.4 nmol/L (P less than 0.001). Procainamide, disopyramide, or mexiletine increased serum digoxin by 0.5 nmol/L in one of 41 patients. Anorexia, nausea, and vomiting develop soon after starting quinidine therapy in 10 of the 22 patients who received quinidine but in only five of the 41 patients who received procainamide, disopyramide, or mexiletine (P less than 0.01). Quinidine prolonged the PR intervals from 160 +/- 14 ms to 183 +/- 26 ms, but procainamide, disopyramide, and mexiletine did not change the PR interval (P less than 0.005). In digitalized patients, quinidine increases serum digoxin concentration, increases digoxin's effect on atrioventricular conduction, and produces more adverse gastrointestinal effects than procainamide, disopyramide, or mexiletine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387000     DOI: 10.7326/0003-4819-92-5-605

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 2.  Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.

Authors:  E M Antman; J M Arnold; P L Friedman; T W Smith
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  High-throughput analysis of drug dissociation from serum proteins using affinity silica monoliths.

Authors:  Michelle J Yoo; David S Hage
Journal:  J Sep Sci       Date:  2011-06-10       Impact factor: 3.645

Review 5.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  The quinidine-digoxin interaction in perspective.

Authors:  B Fichtl; W Doering
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

8.  Digoxin-quinidine interaction in patients with renal failure.

Authors:  R Hirschberg; K Schaefer; D von Herrath; G Kreutz; H Kewitz
Journal:  Klin Wochenschr       Date:  1981-05-15

9.  Quinidine-digoxin interaction: evidence for involvement of an extrarenal mechanism.

Authors:  W Doering; B Fichtl; M Herrmann; E Besenfelder
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 10.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.